Indivior PLC

Chart & Performance

D1W1MN

P/E

27.12

P/S

4.60

EPS

1.52

Div Yield, %

—

Shrs. gr., 5y

-2.67%

Rev. gr., 5y

13.88%

Revenues

1.24b

+4.29%

Net income

210m

+10,400.00%

CFO

-27m

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

As a holding company, Indivior Pharmaceuticals Inc primarily focuses on the development, manufacturing, and distribution of buprenorphine-containing prescription drugs aimed at addressing opioid dependence. Key offerings in its product lineup include Suboxone Film, Suboxone Tablet, and Subutex Tablet. The company's operational footprint spans several geographical areas, namely the United States, the United Kingdom, and the 'Rest of World' segment. Indivior Pharmaceuticals Inc commenced operations on September 26, 2014, and its corporate base is situated in North Chesterfield, VA.

URL

https://www.indivior.com/en

IPO date

Dec 23, 2014

Employees

1,000

Domiciled in

Incorporated in

Valuation

Order:

Title USD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title USD in thousands, except ratios and share amounts	2025‑12	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT